Mikhail Blagosklonny

Mikhail V. Blagosklonny graduated with an MD and PhD from First Pavlov State Medical
University of St. Petersburg, RUS. Dr. Misha V. Blagosklonny subsequently
Moved to the USA, where he was
Awarded the prestigious Fogarty Fellowship from the National Institutes of Health.
During his fellowship in Leonard Neckers’ lab at the National
Cancer Institute (NCI), he was a co-author of 18 publications on
Diversified biomedical themes, like targeting
HSP90, p53, Bcl2, Erb2, and Raf-1. He also was the last author on a clinical phase I/II
Trial paper.
 
After authoring seven papers within the period of a brief yet resulting
Senior research fellowship in the El-Deiry Cancer Research Lab at the University of Pennsylvania,
Dr. Blagosklonny returned to NCI to work with Tito Fojo. Together, they
Published 26 papers. Moreover, Dr. Misha Blagosklonny published a
Lot of experimental research papers and theoretical articles as sole
Writer. These sole-author publications
Highlighted two important topics.
The first of these focused on selectively killing cancer
Cells with deregulated cell cycle or drug resistance via
Confirming their resistance. The outcomes and underlying
Notion were so revolutionary that they were incorrectly cited by
Other scientists as “reversal of resistance, ” even though the paper was
Titled, “Exploiting of drug resistance instead of its reversal. ” One great
Supporter of this concept was the world-famous scientist Arthur Pardee, with whom Dr.
Blagosklonny co-authored a joint article in 2001.
 
The second theme throughout Dr. Blagosklonny’s sole-author publications
Is a research methodology to develop knowledge by
Bringing a few facts together from seemingly unrelated fields.
This results in new notions with testable predictions, which in
Turn can be “tested” by analyzing the literature further. Likewise, the
Notion was co-authored by Arthur Pardee in a 2002 publication in Nature. The
First success of the new research method was the description of the feedback
Regulation of p53, as supported by the discovery of mdm2/p53 loop; and the
Explanation why mutant p53 is always overexpressed, published in 1997. The most
Significant outcome revealed by Dr.
Blagosklonny’s research methodology is the hyperfunction (or quasi-programmed)
Theory of aging and the revelation of rapamycin as an exclusively well-tolerated
Anti-aging medication, published in 2006. As mentioned in Scientific American,
Michael Hall, who discovered mTOR in 1991, gives Dr. Blagosklonny recognition for “connecting dots that others do not even see. ”
 
In 2002, Dr. Blagosklonny became associate professor of medicine at New York Medical College.
He went on to accept responsibilities as a senior scientist at Ordway
Research Institute in Albany, New York, in 2005, prior to accepting another
Position at Roswell Park Cancer Institute as professor of oncology in 2009.
 
Since coming to Roswell Park Comprehensive Cancer Center in 2009, Dr. Blagosklonny has studied the prevention of cancer (an age-related disease) by
Stopping body aging — in other words, “preventing cancer
By remainng young. ” His lab closely worked together with
Andrei Gudkov’s and completed research on the suppression of
Cellular senescence, namely suppression of cellular conversion from healthy quiescence to
Permanent senescence. This led to the discovery of additional anti-aging
Drugs beyond rapamycin. The cell culture studies were
Accompanied by studies in mice, including several models like
Normal and aging mice, p53-deficient mice, and mice on a high-fat diet.
 
Dr. Misha Blagosklonny has also published extensively on the stoppage of cellular senescence by rapamycin as well as other mTOR inhibitors, life
Extension and cancer stoppage in mice, and combinations of anti-
Aging drugs to be appliedamong humans. A rapamycin-based combination of seven clinically available drugs has
Been named the “Koschei Formula” and is now used for the treatment of aging in patients
At the Alan Green Clinic in Little Neck, New York.

https://sbirsource.com/sbir/people/43257-misha-blagosklonny

https://www.onacademic.com/search/list.html?q=Blagosklonny
https://www.nature.com/cdd/editors/editorial-board